5593-20-4 Usage
Chemical Properties
Betamethasone 17,21-dipropionate is Pale Yellow Foam
Originator
Betnovate,Glaxo,UK,1961
Uses
Different sources of media describe the Uses of 5593-20-4 differently. You can refer to the following data:
1. Betamethasone 17,21-dipropionate is used as anti-inflammatory and antibacterial ointment for dermatosis.
2. antiviral
3. Cortico Steroids
Definition
Betamethasone 17,21-dipropionate is a steroid ester that is betamethasone in which the hydroxy hydrogens at positions 17 and 21 are replaced by propanoyl groups. It is used in combination with calcipotriene hydrate, a synthetic vitamin D analogue, for the topical treatment of plaque psoriasi in adult patients.
Manufacturing Process
A solution of 9α-fluoro-11β-hydroxy-16β-methyl-17α,21-(1'-ethyl-1'-
ethoxymethylenedioxy)pregna-1,4-diene-3,20-dione (538 mg) in acetic acid
(20 ml), containing 2 drops of water, was allowed to stand at room
temperature for 5 hours. Dilution of the mixture with water gave a white solid
(457 mg) which, after being filtered off and dried, was recrystallized from
acetone to afford 9α-fluoro-11β,21-dihydroxy-16β-methyl-17α-
propionyloxypregna-1,4-diene-3, 20-dione (361 mg), MP 230°-235°C.
Bethmethasone 17-propionate (812 mg) in pyridine (10 ml) was treated with
propionyl chloride (0.21 ml) at 0°C for 1 hour. Dilution with water and
acidification with dilute hydrochloric acid gave the crude diester.
Recrystallization from acetone-petroleum ether afforded betamethasone
17,21-dipropionate (649 mg), MP 117°C (decomposition).
Brand name
Alphatrex (Savage); Diprolene
(Schering).
Therapeutic Function
Glucocorticoid
Biochem/physiol Actions
Betamethasone 17,21-dipropionate is a glucocorticoid with anti-inflammatory and immunosuppressive activity.
Safety Profile
Poison by subcutaneous andintraperitoneal routes. An experimental teratogen. Otherexperimental reproductive effects. When heated todecomposition it emits toxic fumes of F-.
Check Digit Verification of cas no
The CAS Registry Mumber 5593-20-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,5,9 and 3 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 5593-20:
(6*5)+(5*5)+(4*9)+(3*3)+(2*2)+(1*0)=104
104 % 10 = 4
So 5593-20-4 is a valid CAS Registry Number.
InChI:InChI=1/C27H34ClFO7/c1-5-22(33)35-14-21(32)27(36-23(34)13-28)15(2)10-19-18-7-6-16-11-17(30)8-9-24(16,3)26(18,29)20(31)12-25(19,27)4/h8-9,11,15,18-20,31H,5-7,10,12-14H2,1-4H3/t15-,18-,19-,20-,24-,25-,26?,27-/m0/s1
5593-20-4Relevant articles and documents
Preparation method of betamethasone dipropionate
-
Paragraph 0009; 0044-0062, (2021/05/29)
The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of betamethasone dipropionate. According to the method, betamethason-17-propionate is taken as a raw material, propionic anhydride is taken as a raw material, under the condition that 4-dimethylaminopyridine is taken as a catalyst, betamethasone dipropionate is generated through reaction, and high-purity betamethasone dipropionate is obtained through refining by adopting absolute ethyl alcohol, dichloromethane and normal hexane. The preparation process is simple, the reaction temperature is moderate, and ultralow-temperature or high-temperature reaction is avoided; the solvent or reagent used in the preparation is cheap and easy to obtain, convenient to charge and easy to transport and store; the method has the advantages of small dosage of reaction catalyst, high yield, less generated waste liquid, environmental friendliness and suitability for commercial production.
Pharmaceutical composition
-
, (2008/06/13)
A pharmaceutical composition for dermal use, wherein the composition has a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue, and a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1. The composition can also have at least one solvent component C, where component C is compounds of the general formula R3(OCH2C(R1)H)xOR2(I), wherein x is in the range of 2-60, R1in each of the x units independently is H or CH3, R2is straight chain or branched C1-20alkyl or benzoyl, and R3is H or phenylcarbonyloxy; di-(straight or branched)-C4-10alkyl esters of C4-C8dicarboxylic acids; straight or branched C12-18-alkyl benzoates; straight or branched C2-4-alkyl esters of straight or branched C10-18-alkanoic or -alkenoic acids; propylenglycol diesters with C8-14-alkanoic acids; and branched primary C18-24alkanols.